Guillermo Ramírez-García 1
Pablo García-Molina 2
María Consuelo Flor-Cremades 3
Beatriz Muñoz-Rojas 4
Javier Moleón-Moya 5

1 Master’s Degree in Anthropology and Forensic Genetics, University of Granada (UGR)
2 Master’s Degree in Biotechnology, University of Granada (UGR)
3 Faculty of Pharmacy, University of Granada (UGR)
4 Faculty of Medicine, University of Granada (UGR)
5 Department of Pharmacology, Faculty of Pharmacy, University of Granada (UGR)


Translated by:

Paula Asensi-Gómez 6
Ana Carbajo-García 7
Juan Luis Cobano-Jiménez 8
Elisa Lenker-Andrade 9
Iván Vázquez Delgado 9
Elena Vivas-del-Torno 6

6 Faculty of Human and Social Sciences, University of Comillas
7 Faculty of Human and Social Sciences, University Jaume I (UJI)
8 Faculty of Philosophy and Arts, University of Alcalá (UAH)
9 Faculty of Translation and Interpreting, University of Granada (UGR)


Objectives
The objective of this study is to evaluate the use of hydroxychloroquine and tocilizumab at the beginning of the COVID-19 pandemic and to describe the profile of patients who received these treatments.

Method
The medical records of 403 patients admitted for COVID-19 from March 1 to April 15, 2020 at the San Cecilio University Hospital (Granada, Spain) were analyzed. The data collected included sex, age, days hospitalized, previous pathologies and/or treatments, possible outcomes and drugs administered at the hospital. Student’s t-test and Pearson’s chi-square tests were used as statistical parameters to estimate the possible associations between the defined variables.

Results
Patients with a mean age of 66 years (standard deviation = 15.38), were hospitalized for an average of 15 days (standard deviation = 12.89). The ICU admission rate was 9.93 %, and the death rate added up to 17.37 % of the total number of patients. During the first wave of the pandemic, hydroxychloroquine was administered to the majority of hospitalized patients, while tocilizumab was restricted to the more severe cases.

Conclusions
The results showed two distinct trends in the use of the drugs studied. Tocilizumab was administered to a small number of patients, mainly those with longer length of stay or with complications. Hydroxychloroquine was administered independently of the initial characteristics of patients, especially those who presented comorbidities or took multiple medications.

Keywords: COVID-19, SARS-CoV-2, tocilizumab, hydroxychloroquine, hospitalization



Descargar “Hydroxychloroquine and Tocilizumab in the Treatment of COVID-19: A Longitudinal Observational Study” 2.2-EN.-Hydroxychloroquine-and-Tocilizumab-in-the-Treatment-of-COVID-19-Vol3Num1Mayo2021.pdf – Descargado 8 veces – 435 KB